Corporate calendar for Neumora Therapeutics, Inc. Common Stock (NMRA): upcoming earnings dates, dividend ex-dates and payment dates, stock splits, shareholder meetings and conference calls. Plan your positions around the key catalysts.
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder.
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|---|---|
| 2026-09-14 | ||
| 2026-09-14 | $-0.03 | $278M |
| 2026-09-14 | ||
| 2026-09-14 | $0.05 | $52M |
| 2026-09-14 | $0.12 | $7M |
| 2026-09-14 | $0.20 | $23M |
Price
| Price | $0.77 |
| Market Cap | $143M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADCT · ALMS · AUTL · BCYC · FDMT · FULC · LXRX
Explore sector: Healthcare · Biotechnology
More sections of NMRA: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · News
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks